L 804600
Latest Information Update: 25 Oct 2018
At a glance
- Originator Merck Frosst
- Class Anti-inflammatories
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 12 Jun 2001 No-Development-Reported for Inflammation in Canada (Unknown route)
- 23 Sep 1998 New profile
- 23 Sep 1998 Preclinical development for Inflammation in Canada (Unknown route)